Head-to-head evidence
EDP167 vs NNC0491-6075
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
EDP167
Developed by Eddingpharm (Zhuhai) Co., Ltd.
NCT07412080 · Phase 1 · completed
Participants were randomized to active drug or placebo with full blinding maintained, but the primary endpoint is safety and tolerability rather than a lipid or cardiovascular outcome, and results are not yet posted, so its eventual finding is unknown.
Next expected readout: November 2027 · NCT07799129 (registry estimate)
NNC0491-6075
Developed by Novo Nordisk
NCT05979428 · Phase 1 · completed
Participants were randomly assigned to drug or placebo under quadruple-blind conditions across ascending-dose cohorts, a sound early-safety design, but the primary measure was the number of adverse events rather than a clinical or lipid outcome, and results have not yet been reported.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: EDP167's landscape · NNC0491-6075's landscape